Oral fludarabine

GEG Verhoef

doi:10.4081/hmr.v1i8.301

Authors

GEG Verhoef
support@pagepress.org

Fludarabine is an antimetabolite cytotoxic agent uses for the treatment of patients with various lymphoid malignancies, especially B-cell chronic lymphocytic leukemia (CLL).1 The intravenous formulation of fludarabine has been available for a number of years. It is well established as an effective first-line treatment option in CLL and preferred second-line therapy for patients with CLL initially treated with an alkylating agent-based regimen.2-4 Intravenous fludarabine had been administered as an infusion for 5 consecutive days each month for about 6 months. This schedule creates a number of difficulties with respect to convenience with repeated venipunctures and frequent outpatient visits or hospital admissions.

Supporting Agencies

Verhoef, G. (2009). Oral fludarabine. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.301

Download Citation

Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations